Vadadustat - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for vadadustat and what is the scope of freedom to operate?
Vadadustat
is the generic ingredient in one branded drug marketed by Akebia and is included in one NDA. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Vadadustat has two hundred and eighteen patent family members in forty-three countries.
One supplier is listed for this compound.
Summary for vadadustat
| International Patents: | 218 |
| US Patents: | 13 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 29 |
| Patent Applications: | 117 |
| What excipients (inactive ingredients) are in vadadustat? | vadadustat excipients list |
| DailyMed Link: | vadadustat at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for vadadustat
Generic Entry Date for vadadustat*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for vadadustat
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Akebia Therapeutics Inc. | Phase 2 |
| The University of Texas Health Science Center, Houston | Phase 2 |
| United States Department of Defense | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for vadadustat
US Patents and Regulatory Information for vadadustat
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-001 | Mar 27, 2024 | RX | Yes | No | RE47437 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-001 | Mar 27, 2024 | RX | Yes | No | 8,598,210 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-001 | Mar 27, 2024 | RX | Yes | No | 9,701,636 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for vadadustat
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Akebia Europe Limited | Vafseo | vadadustat | EMEA/H/C/005131 Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. |
Authorised | no | no | no | 2023-04-24 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for vadadustat
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 2659682 | INHIBITEURS DE LA PROLYL HYDROXYLASE ET PROCEDES D'UTILISATION (PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE) | ⤷ Subscribe |
| Denmark | 3277270 | ⤷ Subscribe | |
| Israel | 281058 | הרכבים ושיטות לטיפול באנמיה (Compositions and methods for treating anemia) | ⤷ Subscribe |
| >Country | >Patent Number | >Title | >Estimated Expiration |
